WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the release of its 2025 Sustainability Report. The report highlights ...

The central fair value estimate for WuXi AppTec has shifted from CN¥129.89 to CN¥137.83, putting a refreshed price target in focus for investors. Bullish and bearish analysts are reading this change ...

The Chinese company’s revenue rose nearly 29 per cent to 12.44 billion yuan, while profit surged about 27 per cent to 4.65 ...

WuXi AppTec Co., a leading drug development and manufacturing services provider, saw its shares climb sharply on Tuesday ...

SAN DIEGO , CA, UNITED STATES, April 17, 2026 /EINPresswire.com/ -- In today’s life sciences landscape, the journey ...

Investing.com-- Shares of WuXi AppTec Co (HK:2359) (SS:603259) rose sharply on Tuesday after the drug development services ...

SAN DIEGO , CA, UNITED STATES, April 14, 2026 /EINPresswire.com/ -- Since its foundation, WuXi AppTec has helped ...

WuXi's bioconjugation spinoff is set to break free onto the Hong Kong Stock Exchange this month, with plans to funnel hundreds of millions of dollars in proceeds back into its Asian manufacturing ...

ET Net News Agency, 28 April 2026] A direct manual trade of 292,700 shares of WUXI APPTEC (02359) was registered at 10:47a.m. The deal amounted to HK$42.57m, or at HK$145.45 per ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

In a complex therapeutic landscape, WuXi AppTec is simplifying the path from discovery to patient. Find out how.

The city of Wuxi in East China's Jiangsu province has been an industrial leader in the country for more than 100 years in terms of manufacturing prowess. Today it continues to lead with its ...